阻断型抗CD55和抗CD59增强曲妥珠单克隆抗体对非小细胞肺癌分子靶向治疗作用的初步探讨  

Preliminary study of increasing kill activity of trastuzumab with blocking anti-CD55 and anti-CD59 antibodies

作　　者：赵伟鹏[1] 朱波[1] 陈正堂[1] 

机构地区：[1]第三军医大学新桥医院全军肿瘤研究所,重庆400037

出　　处：《中国医师进修杂志（内科版）》2007年第1期15-17,共3页Chinese Journal of Postgraduates of Medicine

基　　金：国家自然科学基金资助项目（30200120、30300150、30400407）

摘　　要：目的检测CD55和CD59在非小细胞肺癌（NSCLC）细胞株的表达情况，寻找增强曲妥珠单克隆抗体（赫赛汀）特异性杀伤肿瘤细胞的方法。方法细胞免疫组化法检测NSCLC细胞株的CD55和CD59表达；赫赛汀激活补体后，采用CCK-8法检测细胞溶解率，合用阻断型抗CD55和/或抗CD59，比较合用与否的差别。结果免疫组化结果显示CD55和CD59在NSCLC细胞株上高表达。阻断型抗CD55和/或抗CD59作用于肿瘤细胞后溶解率明显增加（P〈0．05）。结论阻断型抗CD55及抗CD59可以增强赫赛汀的杀伤肿瘤细胞能力，为肿瘤的治疗提供了新的思路。Objective To investignte the expression of CD55 and CD59 in non-small cell lung carcinoma （NSCLC） cell lines and seek the novel method to enhance cytotoxicity stimulated by lzastuzumab （herceptin）. Methods The expression of CDss and CD59 were determined with immunohistochemistry. Furthermore, the NSCLC cells were incubated with hereeptin with blocking anti-CDss and/or anti-CD59 antibodies. Cell lysis action was quantitated by CCK-8 in vitro. Results There were CDss and CD59 overexpression among NSCLC cells. There were statistical significance between adding blocking anti-CD55 and/or anti-CD59 antibody and not adding. Conclusion Blocking anti-CD55 and anti-CD59 antibodies may represent a therapeutic tool to increase the complement-dependent killing activity of herceptin,

关 键 词：曲妥珠单克隆抗体 CD55 CD59 

分 类 号：R734.2[医药卫生—肿瘤]